

Company Overview

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system malignancies. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

Additionally, the Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.

CNS Pharmaceuticals Announces Pricing of \$4.0 Million Public Offering

Jan 29 2024, 9:00 PM EST

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

Jan 18 2024, 8:45 AM EST

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Jan 17 2024, 8:45 AM EST

Stock Overview

Symbol	CNSP
Exchange	Nasdaq
Market Cap	1.82m
Last Price	\$0.34
52-Week Range	\$0.22 - \$4.40

Investor Relations

JTC Team, LLC
Jenene Thomas
T: 833-475-8247
cns@jtcir.com

03/19/2024 04:00 PM EDT

Management Team

John M. Climaco, JD

Chief Executive Officer

Christopher S. Downs, CPA

Chief Financial Officer

Sandra L. Silberman, MD, PhD

Chief Medical Officer

Donald Picker, PhD

Chief Science Officer

CNS Pharmaceuticals, Inc.

2100 West Loop South
Suite 900
Houston, TX 77027

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.